Reducing chemotherapy-associated toxicity in elderly cancer patients

Cancer Treatment Reviews

Volumn 22, Issue 3, 1996, Pages 223-244

  Zagonel, Vittorina ^a   Fratino, Lucia ^a   Sacco, Cosimo ^a   Babare, Roberta ^a   Spazzapan, Simon ^a   Gattei, Valter ^a   Improta, Salvatore ^a   Pinto, Antonio ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; GLUTAMIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN; INTERLEUKIN 3; LAXATIVE; MESNA; MITOXANTRONE; NITROSOUREA; RAZOXANE; RETINOIC ACID; SODIUM THIOSULFATE; STEM CELL FACTOR; TETRAHYDROURIDINE; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

AGED; ANTIBIOTIC THERAPY; BLADDER DISEASE; BONE MARROW TOXICITY; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CELL PROTECTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; HEART PROTECTION; HUMAN; IMMUNOTOXICITY; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW;

EID: 0029744405     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90003-1     Document Type: Article

References (135)

1. Schwartsmann, G., Dekker, A. W. & Verhoff, J. (1995) Complications of cytotoxic therapy. In: Peckham, M., Pinedo, H. & Veronesi, U., eds, Oxford Textbook of Oncology. Oxford University Press, pp. 2307-3227.
2. Hryniuk, W. M. (1988) The importance of dose intensity in the outcome of chemotherapy. In: De Vita, V. T., Hellman, S. & Rosenberg, S. A., eds, Important Advances in Oncology. Philadelphia: J. B. Lippincott Company, pp. 121-142.
3. Kwak, L. W., Halper, J., Olshen, R. A. & Horning, S. L. (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J. Clin. Oncol. 8: 963-977.
4. Epelbaum, R., Faraggi, D., Ben-Arie, Y. et al. (1990) Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 66: 1124-1129.
5. Bonadonna, G. & Valagussa, P. (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med. 304: 10-15.
6. O'Reilly, S. E., Connors, J. M., Howdle, S. et al. (1993) In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy. J. Clin. Oncol. 11: 2250-2257.
7. Tirelli, U., Zagonel, V., Serraino, D. et al. (1988) Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: A retrospective European Organization for Research and Treatment of Cancer Lymphoma Group study. J. Clin. Oncol. 6: 1708-1713.
8. Dixon, D. O., Neilan, B., Jones, S. E. et al. (1986) Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: The Southwest Oncology Group experience. J. Clin. Oncol. 4: 295-305.
9. Vose J. M, Armitage, J. O, Weisenburger, D. D. et al. (1988) The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 6: 1838-1844.
10. Monfardini, S., Aapro, M., Ferucci, L. et al (1993) Commission of the European Communities "Europe Against Cancer" programme. European School of Oncology advisory report. Cancer treatment in the elderly. Eur. J. Cancer. 29A: 2325-2330.
11. Kennedy, B. J. (1991) Needed clinical trials for older patients. J. Clin. Oncol. 9: 718-720.
12. Borkowski, J. M., Duerr, M., Donehower, R. C. et al. (1994) Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother. Pharmacol. 33(6): 493-496.
13. Einhorn, L. H. (1992) Approaches to drug therapy in older cancer patients. Oncology 6: 69-73.
14. Balducci, L. & Mowry, K. (1992) Pharmacology and organ toxicity of chemotherapy in older patients. Oncology 6: 62-68.
15. Raghavan, D., Findlay, M. P. N. & McNeil, E. B. (1995) Cancer in the elderly. In: Peckham, M., Pinedo, H., Veronesi, U., eds, Oxford Textbook of Oncology. Oxford: Oxford University Press, pp. 2169-2189.
16. Conti, J. A. & Christman, K. (1995) Cancer chemotherapy in the elderly. J. Clin. Gastroenterol. 21: 65-71.
17. Lieschke, G. J. & Burgess, A. W. (1992) Granulocyte colony stimulating factor and granulocytemacrophage colony stimulating factor. N. Engl. J. Med. 327: 28-35, 99-106.
18. Begg, C. B. & Carbone, P. P. (1983) Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 52: 1986-1992.
19. Sank, W. A. Jr. & Balducci, L. (1992) Recombinant hemopoietic growth factors: Comparative response in younger and older subjects. J. Am. Geriar. Soc. 40: 151-154.
20. Vose, J. M. (1995) Cytokine use in the older patient. Semin. Oncol. 22 (Suppl. 1): 6-8.
21. Zagonel, V., Babare, R., Merola, M. C. et al. (1994) Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann. Oncol. 5 (Suppl. 2): 127-132.
22. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors (1994) Evidence-based, clinical practice guidelines. J. Clin. Oncol. 12: 2471-2508.
23. Lyman, G. H., Lyman, C. G., Sanderson, R. A. & Balducci, L. (1993) Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J. Natl. Cancer Inst. 85: 488-493.
24. Armitage, J. O. & Potter, J. F. (1984) Aggressive chemotherapy for diffuse histocytic lymphoma in the elderly: Increased complications of advancing age. J. Am. Geriatr. Soc. 32: 269-273.
25. Cheson, B. D. (1995) Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol. 13: 2431-2448.
26. Chatta, G. S., Andrews, R. G., Rodger, E., Shragg, M., Hammond, W. P. & Dale, D. C. (1993) Hematopoietic progenitors and aging: Alternations in granulocytic precursors and responsiveness to recombinant human G-CSF, GM-CSF, and IL-3. J. Gerontol. 48: M207.
27. Chatta, G. S., Price, T. H., Allen, R. C. & Dale, D. C. (1994). Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 84: 2923-2929.
28. Chatta, G. S., Price, T. H., Stratton, J. R. & Dale, D. C. (1994) Aging and marrow neutrophil reserves. J. Am. Geriatr. Soc. 42: 77-81.
29. Lipschitz, D., Udupa, K., Milton, K. & Thompson, C. (1984) Effects of age on hematopoiesis in man. Blood 63: 502-509.
30. Mori, M., Tanaka, A. & Sato, N. (1986) Hematopoietic stem cells in elderly people. Mech. Aging. Dev. 37: 41-47.
31. Lee, M., Segal, G. & Bagby, G. (1989) The hematopoietic microenvironment in the elderly: defects in IL-1 induced CSF expression in vitro. Exp. Hematol 17: 952-956.
32. Buchanan, J. & Rothstein, G. (1989) Deficient growth factor production as a cause of hematopoietic dysregulation in aged subjects. Clin. Res. 37: 149A.
33. Baldwin, J. (1988) Hematopoietic function in the elderly. Arch. Intern. Med. 148: 2544.
34. Tirelli, U., Zagonel, V., Errante, D. et al. (1992) A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavourable non-Hodgkin's lymphoma. J. Clin. Oncol. 10: 228-236.
35. Monfardini, S., Sacco, C., Babare, R., Merola, M. C., Carbone, A. & Zagonel, V. (1994) VP-16, mitoxantrone and prednimustine (VMP) with or without G-CSF in patients (PTS) with non-Hodgkin's lymphomas (NHL) older than 70 years (YRS). Proc. Am. Soc. Clin. Oncol. 13: 377.
36. Vose, J. M. & Armitage, J. O. (1995) Clinical applications of hematopoietic growth factors. J. Clin. Oncol. 13: 1023-1035.
37. Aoki, Y., Hiromatsu, K., Kobayashi, N. et al. (1995) Protective effect of granulocyte colony-stimulating factor against T-cell-mediated lethal shock triggered by superantigens. Blood 86: 1420-1427.
38. Aglietta, M., Piacibello, W., Sanavio, F. et al. (1989) Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony stimulating factor. J. Clin. Invest. 83: 551-557.
39. Tafuto, S., Abate, G., D'Andrea, P. et al. (1995) A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. Eur. J. Cancer. 31A: 46-49.
40. Miller, J. A. & Beveridge, R. A. (1994) A comparison of efficacy of GM-CSF and G-GSF in the therapeutic setting of chemotherapy induced neutropenia. Blood 84 (Suppl.): 78a.
41. Chi, K. H., Chen, Ch. H., Chan, W. K. et al. (1995) Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J. Clin. Oncol. 13: 2620-2628.
42. Bartley,T. D., Bogenberger, J., Hunt, P. et al. (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77: 1117-1124.
43. de Sauvage, F. J., Hass, P. E., Spencer, S. D. et al. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369: 533-538.
44. Small, D., Levenstein, M., Kim, E. et al. (1994) STK-1, the human homolog of the flk-2/flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl. Acad. Sci. USA 91: 459-463.
45. Hannum, C., Culpepper, J., Campbell, D. et al. (1994) Ligand for flt-3/flt-2 receptor tyrosine kinase regulates growth of hematopoietic stem cells and is encoded by variant RNAs. Nature 368: 643-648.
46. Metcalf, D. (1993) Hematopoietic regulators: redundancy or subtlety? Blood 12: 3515-3523.
47. Skilings, J. R., Sridhar, F. G., Wong, C. & Paddock, L. (1993) The frequency of red cell transfusion for anemia in patients receiving chemotherapy: A retrospective cohort study. Am. J. Clin. Oncol. 16: 22-25.
48. Abels, R. I. (1992) Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin. Oncol. 19 (Suppl. 8): 29-35.
49. Henry, D. H. & Abels, R. I. (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin. Oncol. 21 (Suppl. 3): 21-28.
50. Denton, T. A., Diamond, G. A., Matloff, J. M. & Gray, R. J. (1994) Anemia therapy: Individual benefit and social cost. Semin. Oncol. 21 (Suppl. 3): 29-35.
51. Wei, J. Y. (1995) Cardiovascular comorbidity in the older cancer patient. Semin. Oncol. 22 (Suppl. 1): 9-10.
52. Balducci, L., Mowrey, K. & Parker, M. (1992) Pharmacology of antineoplastic agents in older patients. In: Balducci, L., Lyman, G. H. & Ershler, W. B., eds, Geriatric Oncology. Philadelphia: J. B. Lippincott Company, pp. 169-180.
53. Allen, A. (1992) The cardiotoxicity of chemotherapeutic drugs. Semin. Oncol. 19: 529-542.
54. Buzdar, A. V., Marcus, C., Smith, T. L. & Blumenschien, G. R. (1985) Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55: 2761-2765.
55. Hortobagyi G. N., Frye, D., Buzdar, A. U. et al. (1989) Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 3: 37-45.
56. Weiss, A. J., Metter, G. E., Flztcher, W. S., Wilson WL., Grage, T. B. & Ramirez, G. (1976) Studies on andriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Resp. 60: 813-822.
57. Bonadonna, G., Gianni, L., Santoro, A et al. (1993) Drugs ten years later: Epirubicin. Ann. Oncol. 4: 359-369.
58. Petti, M. C. & Mandelli, F. (1989) ldarubicin in acute leukemias: Experience of the Italian Cooperative Group GIMEMA. Semin. Oncol. 16: 10-15.
59. Benjamin, R. S. (1995) Rationale for the use of mitoxantrone in the older patient: Cardiac toxicity. Semin. Oncol. 22 (Suppl. 1): 11-13.
60. Henderson, I. C., Allegra, J. C., Woodcock Wolff, S. et al. (1989) Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7: 560-571.
61. Neithart, J. A., Gochnour, D., Roach, R., Hoth, D. & Young, D. (1986) A comparison of mitoxantrone and doxorubicin in breast cancer. J. Clin. Oncol. 4: 672-677.
62. Covan, J. D., Neidhart, J., McClure, S. et al. (1991) Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group study. J. Natl. Cancer Inst. 83: 1077-1084.
63. Sonneveld, P., de Ridder, M., van der Leile, H. et al. (1995) Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy. J. Clin. Oncol 13: 2530-2539.
64. Tirelli, U., Van Glabbeke, M., Teodorovic, I et al. (1995) A randomized comparison of CHOP versus a new combination of VP16, mitoxantrone and prednimustine (VMP) in patients (PTS) >70 years of age with intermediate high grade NHL: An EORTC lymphoma group study. Proc. Am. Soc. Clin. Oncol. 14:398.
65. Speyer J. L., Green M. D., Kramer E. et al. (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl J. Med. 318: 745-752.
66. Koning, J., Palmer, P., Franks, C. R. et al. (1991) Cardioxane-ICRF-187. Towards anticancer drug specificity through selective toxicity reduction. Cancer Treat. Rev. 18: 1-19.
67. Hershko, C., Link, G., Tzahor, M. & Pinson, A. (1993) The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk. Lymph. 11: 207-214.
68. Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A. et al. (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 10: 117-127.
69. Michelotti, A., Venturini, M., Conte, P. F. et al. (1995) Cardioxane (ICRF-187) protects against epirubicin (EPI) induced cardiomyopathy in advanced breast cancer (ABC) patients: A phase III study. Proc. Am. Soc. Clin. Oncol. 14: 98.
70. Vici, P., Di Lauro, L., Ferraironi A. et al. (1994) A randomized trial of dexrazoxane (DEX) cardioprotection in patients (PTS) with metastatic breast cancer (MBC) and advanced soft tissue sarcoma (ASTS) treated with high-dose epirubicin (EPI). Proc. Am. Soc. Clin. Oncol. 13: 94.
71. Patterson, W. P. & Reams, G. P. (1992) Renal toxicities of chemotherapy. Semin. Oncol. 19: 521-528.
72. Kintzel, P. E. & Dorr, R. T. (1995) Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat. Rev. 21: 33-64.
73. Hrushesky, W. J. M., Shimp, W. & Kennedy, B. J. (1984) Lack of age-dependant cisplatin nephrotoxicity. Am. J. Med. 75: 578-586.
74. Lichtman, S. M., Buchholtz, M., Marino, J. et al. (1992) Use of cisplatin or elderly patients. Age and Ageing 21: 202-204.
75. Thyss, A., Saudes, L., Otto, J. et al. (1994) Renal tolerance of cisplatin in patients more than 80 years old. J. Clin. Oncol. 12: 2121-2125.
76. Pfeifle, C. E., Howell, S. B., Felthouse, R. D. et al. (1985) High-dose cisplatin with sodium thiosulfate protection. J. Clin. Oncol. 3: 237-244.
77. Quazi, R., Chang, A. Y. C., Borch, R. F. et al. (1988) Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J. Natl. Cancer Inst. 80: 1486-1488.
78. Berry, J. M., Jacobs, Ch., Sikic, B., Halsey, J. & Borch, R. F. (1990) Modification of cisplatin toxicity with diethyldithiocarbamate. J. Clin. Oncol. 1585-1590.
79. Glover, D. J., Glick, J. H., Weiler, C., Fox, K. & Guerry, D. (1987) WR-2721 and high dose cisplatin: An active combination in the treatment of metastatic melanoma. J. Clin. Oncol. 5: 574-578.
80. Treskes, M. & van der Vijh, W. J. F. (1993) WR-2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother. Pharmacol. 33: 93-106.
81. Rheumatoid Arthritis Clinical Trial Archive Group (1995) The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J. Rheumatol. 22: 218-223.
82. Christensen, M. L. & Stewart, C. F. (1989) Evaluation of aminoglycoside disposition in patients previously treated with cisplatin. Ther. Drug Monit. 11: 631-636.
83. Fleming, R. A. & Capizzi, R. L. (1993) General aspects of cancer chemotherapy in the aged. In: Yang, S. S. & Warner, H. R., eds, The Underlying Molecular, Cellular, and Immunological Factors in Cancer and Aging. New York: Plenum Press, pp. 271-289.
84. Mitchell, E. P. (1992) Gastrointestinal toxicity of chemotherapeutic agents. Semin. Oncol. 19: 566-579.
85. McMillan, S. (1992) Intensity of pain, nausea, and vomiting in relationship to age in persons with cancer. In: Balducci, L., Lyman, G. H. & Ershler, W. B., eds, Geriatric Oncology. Philadelphia: J. B. Lippincott, pp. 326-331.
86. Mahood, D. J., Dose, A. M., Loprinzi, C. L. et al. (1991) Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J. Clin. Oncol. 9: 449-452.
87. Finch, P. W., Rubin, J. S., Miki, T., Ron D. & Aaronson, S. A. (1989) Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 245: 752-755.
88. Werner, S., Peters, K. G., Longaker, M. T., Fuller-Pace, F., Banda, M. J. & Williams, L. T. (1992) Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc. Natl. Acad. Sci. USA 89: 6896-6900.
89. Petrelli, N., Douglass, H. O., Herrera, L. et al. (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma. A prospective randomized phase III trial. J. Clin. Oncol. 7: 1419-1426.
90. Stein, B. N., Ptrelli, N. J., Douglass, H. O., Driscoll, D. L., Arcangeli, G. & Meropol, N. J. (1995) Age and sex are independent predictors of 5-fluorouracil toxicity: Analysis of a large scale phase III trial. Cancer 75: 11-17.
91. Morley, J. E. (1986) Nutritional status of the elderly. Am. J. Med. 81: 679-698.
92. De Cicco, M., Panarello, G., Fantin, D. et al. (1993) Parenteral nutrition in cancer patients receiving chemotherapy: Effects on toxicity and nutritional status. J. Patenter. Enterai. Nutr. 17: 513-518.
93. Popper, H. (1986) Aging and the liver. Prog. Liver Dis. 8: 659-683.
94. Schinella, M., Tellini, U., Pravadelli, B. & Caputo, M. (1994) Monoethylglycine-xylilide: Levels in elderly patients. Eur. J. Lab. Med. 2: 108-111.
95. Cannizzaro, R., Robieux, I., Valentini, M. et al. (1996) Liver function assessment by MEGX: Application to oncology. Ann. New York AC Science (in press).
96. Tuxen, M. K. & Hansen, S. W. (1994) Neurotoxicity secondary to antineoplastic drugs. Cancer Treat. Rev. 20: 191-214.
97. Jackson, D. V., Wells, H. B., Atkins, J. N. et al. (1988) Amelioration of vincristine neurotoxicity by glutamic acid. Am. J. Med. 84: 1016-1022.
98. Babare, R., Zagonel, V., Ferrara, F et al. (1994) Cost-benefit of chemotherapy on refractory-resistant multiple myeloma (MM): VAD vs VID combination. Ann. Oncol. 5 (Suppl. 8): 125.
99. Gottlieb, D., Bradstock, K., Koutts, J., Robertson, T., Lee, Ch. & Castaldi, P. (1987) The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 60: 1439-1441.
100. Lopez, J. A. & Agarwal R. P. (1984) Acute cerebellar toxicity after high dose cytarabine associated with CNS accumulation of its metabolic, uracil arabinoside. Cancer Treat. Rev. 68: 1309-1310.
101. Feldman, E. J. (1995) Acute myelogenous leukemia in the older patient. Semin. Oncol. 22: 21-24.
102. Kreis, W., Chan, K., Budman, D. R. et al. (1988) Effect of tetrahydrouridine on the clinical pharmacology of 1-β-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Cancer Res. 48: 1337-1342.
103. Ginsberg, S. L. & Comis, R. L. (1982) The pulmonary toxicity of antineoplastic agents. Semin. Oncol. 9: 34-51.
104. Mahler, D. A., Rosiello, R. A. & Lorie, J. (1986) The aging lung. Geriatr. Clin. North Am. 2: 216-225.
105. Sostman, H. D., Matthay, R. A. & Putnam, C. E. (1977) Cytotoxic induced lung disease. Am. J. Med. 62: 608-615.
106. Lazo, J. S. & Dale, G. H. (1990) The molecular basis of interstitial pulmonary fibrosis caused by antineoplastic agents. Cancer Treat. Rev. 17: 165-167.
107. Sugahara, K., Iyama, K., Sakanashi, Y. & Sano, K. (1995) Keratinocyte growth factor (KGF) prevents bleomycin-induced lung fibrosis in rats. Mol. Biol. Cell 6 (Suppl.): 203a.
108. Gaetani, P., Silvani, V., Butti, G., Spanu, G., Rossi, A. & Knerich, R. (1987) Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention. Eur. J. Cancer Clin. Oncol. 23: 267-271.
109. Hodes, R. J. (1995) Molecular alterations in the aging immune system. J. Exp. Med. 182: 1-3.
110. + T lymphopenia in older persons. J. Am. Geriatr. Soc. 42: 1291-1294.
111. Roberts-Thomson, I. C., Whittingham, S., Youngchaiyud, U. & Mackay, I. R. (1974) Ageing, immune response, and mortality. Lancet 2: 368-370.
112. + cells. Eur. J. Immunol. 21: 273-281.
113. Gabriel, H., Smidt, B. & Kindermann, W. (1993) Age-related increase of CD45RCT lymphocytes in physically active adults. Eur. J. Immunol. 23: 2704-2706.
114. Mackall, C. L., Fleisher, T. A., Brown, M. R. et al. (1995) Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N. Engl. J. Med. 332: 143-149.
115. Yuhas, J. M. (1980) Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 40: 1519-1524.
116. Capizzi, R. L. (1994) Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): Clinical experiences. Semin. Oncol. 21 (Suppl. 11): 8-15.
117. Capizzi, R. L., Scheffler, B. J. & Schein, P. S. (1993) Amifostine-mediated protection of normal marrow from cytotoxic chemotherapy. Cancer 72: 3495-3501.
118. van der Vijgh, W. J. F. & Peters, G. J. (1994) Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): Preclinical aspects. Semin. Oncol. 21 (Suppl. 11): 2-7.
119. Click, J., Kemp, G., Rose, P., McCulloch, W., Scheffler, B. & Schein, P. (1992) A randomized trial of cyclophosphamide and cisplatin+WR-2721 in the treatment of advanced epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 11: 109.
120. Bukowski, R. M., Capizzi, R. L., Alberts, D. S. et al. (1995) Ethyol: Current and future applications in cytoprotection. International Congress Abstract Booklet, Monte Carlo, 28 September-1 October, 1995.
121. Dounay, L., Hu, Ch., Giarratana, M. C. & Gorin, N. C. (1994) Comparative effects of amifostine (ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Semin. Oncol. 21 (Supp. 11): 16-20.
122. Patchen, M. L. & MacVittle, T. J. (1994) Granulocyte Colony-stimulating factor and amifostine (ethyol) synergize to enhance hemopoietic reconstruction and increase survival in irradiated animals. Semin. Oncol. 21 (Suppl. 11): 26-32.
123. Zagonel, V., Pinto, A., Serraino, D. et al. (1994) Lung cancer in the elderly. Cancer Treat. Res. 20: 315-329.
124. Repetto, L., Vercelli, M., Simoni, C. et al. (1994) Comorbidity among elderly patients with and without cancer. Proc. Am. Soc. Oncol. 13: 1625.
125. Monfardinit, S., Ferrucci, L., Fratino, L., Del Lungo, I., Serraino & Zagonel, V. (1996) Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 77: 395-401.
126. Monfardini, S., Fratino, L., Zagonel, V. & Serraino, D. (1995) How much does performance status correlate with multidimensional geriatric assessment in elderly patients with cancer (EPC)? Eur. J. Cancer 31A (Suppl. 5): 255 (abstr).
127. Giovanazzi-Bannon, S., Rademaker, A., Lai, G. & Benson, A. B. (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study. J. Clin. Oncol. 12: 2447-2452.
128. Monfardini, S., Sorio, R., Rendard, J., Kaye, S. & van Glabbeke, M. (1993) Entry of elderly patients in EORTC new drug development studies. Proc. Am. Soc. Clin. Oncol. 12: 132.
129. Winer, E. P., Chu, L. & Spicer, D. V. (1995) Oral vinorelbine (navelbine) in the treatment of advanced breast cancer. Semin. Oncol. 22: 72-79.
130. Armitage, J. O. (1993) Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med. 328: 1023-1030.
131. Coiffier, B. (1994) What treatment for elderly patients with aggressive lymphoma?. Ann. Oncol. 5: 873-875.
132. Monfardini, S. (1996) What do we know on variables influencing clinical decision-making in elderly cancer patients? Eur. J. Cancer (in press).
133. Gianni, A. M., Siena, S., Bregni, M et al. (1991) Prolonged disease-free survival after highdose sequential chemoradiotherapy and hemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann. Oncol. 2: 645-653.
134. Coiffier, B., Philip, T., Burnett, A. K. & Symann, M. L. (1993) Consensus Conference on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies. J. Clin. Oncol. 12: 266-331.
135. Armitage, J. O. (1994) Bone marrow transplantation. N. Engl. J. Med. 330: 827-838.